Osteogenesis Imperfecta

OSTEOGENESIS IMPERFECTA (OI)

Definition

• Also referred to as “brittle bone disease.”
• Rare hereditary connective tissue disorder (~1 case per 200,000 live births).
• Marked variability in clinical presentation:
  • Moderate to severe forms often present in infancy (fractures with little/no trauma).
  • Mild forms may only appear later (adulthood) with premature osteoporosis.

Etiology & Genetic Background

• ~90% of cases: Autosomal dominant germline mutations in type I collagen genes—COL1A1 and COL1A2.
  • Collagen type I is crucial for normal bones, sclerae, tendons, ligaments, teeth, and skin.
  • Disease can result from abnormal structure or reduced production of type I collagen.
• Mutations in other collagen-related genes (e.g., encoding cartilage-associated proteins) found in a minority of OI patients.
• Intra-familial variability: Patients with the same mutation may have different severities (involving other genetic or environmental factors).

Key Clinical Features

• Recurrent bone fractures (often minimal or no trauma).
• Blue sclerae (translucent sclera revealing underlying uveal tissue).
• Opalescent teeth (dentinogenesis imperfecta) → teeth appear grayish or bluish, may be fragile.
• Easy bruising of tissues.
• Basilar skull deformities with possible neurological complications.
• Hearing loss (due to fracture of ossicles or inner ear involvement).
• Ligament laxity with hypermobility.

Clinical Subtypes

1. Type I OI (Mild)
   • Typically mild manifestations:
     • Infrequent fractures (long bones, ribs).
     • Normal stature, possible premature osteoporosis.
     • Mild scoliosis can occur.
     • Blue sclerae.
     • Teeth: normal appearance or opalescent.
     • Early-onset hearing loss is common.
   • Often related to a COL1A1 allele deletion → normal collagen structure but reduced overall production.
2. Type II OI (Lethal Perinatal)
   • Multiple severe fractures in utero or at birth.
   • Typically fatal shortly after delivery (respiratory failure).
3. Types III, IV, V, VI, VII, and VIII
   • Severe bone fragility with frequent fractures and limb deformities.
   • Progressive skeletal deformities:
     • Bowed long bones, scoliosis, short stature.
     • Basilar skull changes → possible nerve compression.
     • Hearing loss if ossicles are affected.
   • Joint hypermobility can be present.
   • Type III: progressive deforming form leading to wheelchair use.
   • Type IV: somewhat less growth retardation vs. Type III; may have normal sclera.
   • Type V: “Congenital brittle bones with redundant callus;” no dentinogenesis imperfecta.
   • Type VI: “Congenital brittle bones with mineralization defect;” accumulation of osteoid in bone tissue.
   • Type VII: Rare, recessive, with rhizomelia (shortening near proximal limb segments).
   • Type VIII: Recessive, prolyl 3-hydroxylase 1 deficiency → severely undermineralized bone matrix.

Laboratory Findings

• Calcium, phosphorus, PTH often normal in typical OI.
• Hypercalciuria may occur, correlates with disease severity.
• Bone markers:
  • Formation markers (bone-specific alkaline phosphatase, osteocalcin, collagen propeptides) may be low in severe disease (impaired osteoblast function).
  • Resorption markers (urinary hydroxyproline, N/C-telopeptide crosslinks) may be high, reflecting increased collagen breakdown.
• Bone biopsy typically not necessary; if done, may show:
  • Disorganized bone architecture.
  • High turnover with decreased cortical width, trabecular number, and cancellous bone volume.

Differential Diagnosis

• Rickets (various forms).
• Child abuse (non-accidental fractures).
• Idiopathic juvenile osteoporosis.
• Hypophosphatasia (tissue-nonspecific alkaline phosphatase deficiency).
• Juvenile Paget disease.
• Fibrous dysplasia, Ehlers-Danlos syndrome, Menkes disease, Cole-Carpenter syndrome.

Diagnosis

• Clinical diagnosis: Recurrent fractures, blue sclerae, family history, dentinogenesis imperfecta, hearing loss.
• Genetic testing: Mutational analysis of COL1A1 and COL1A2.
• Skeletal radiographs: May reveal osteopenia, thin cortices, multiple fractures in different healing stages.

Treatment & Management

• Team approach: Genetics, orthopedics, neurology, physical/occupational therapy, dental, ENT, psychology, endocrinology.
• Goals:
  • Reduce fracture frequency.
  • Maximize mobility and independence.
  • Prevent/managing deformities (e.g., scoliosis).
  • Control pain.
• Monitoring:
  • Bone mineral density (BMD) with DXA.
  • Frequency of fractures.
  • Hearing tests, dental evaluations.
  • For Type III OI → annual echocardiogram (to detect aortic root dilation/valvular issues).
• Pharmacologic therapy:
  • Bisphosphonates (e.g., pamidronate, alendronate) → shown to increase BMD, decrease fractures, and improve mobility.
  • Monitor for any “mineralization defect” OI types (e.g., Type VI) where bisphosphonates may be less effective or contraindicated.
  • Other treatments under investigation: growth hormone, gene therapy, bone marrow transplant.
• Prognosis:
  • Type I: Normal life expectancy; mild disease.
  • More severe forms: Shortened lifespan, linked to thoracic deformities and related complications.
  • Skilled orthopedic interventions and bracing may reduce complications and improve quality of life.